Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Coupang is an e-commerce platform that offers a wide variety of products, including apparel, electronics, and home goods.
Skillz is a marketplace platform for competition-based mobile games.
LianBio aims to develop and accelerate availability of paradigm-shifting medicines to patients in China.
ACV is a full-service dealer marketplace that runs online automotive auctions.
PMV Pharmaceuticals is a developer of p53-targeted small molecule drugs for the treatment of cancer.
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
Forty Seven is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways.
The Honest Company is a consumer products company that offers baby, personal care, and beauty products.
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Nightstar is biopharmaceutical company, focused on developing gene therapies for retinal dystrophies.
Rhythm Metabolic develops a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies.
Nanigans provides an advertising automation software that powers the in-house performance marketing teams.
Wellington Management has invested in 278 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Wellington Management's top investment sectors include Biotechnology, Health Care, Biopharma, Health Diagnostics, Medical. The firm invests across 39 different industry categories.
Among tracked funding rounds, LianBio received $310.0M in a Series A round. Wellington Management's total known invested capital is $62.7B.
Wellington Management's average investment size is $277.4M across its portfolio of 278 companies.
Recent Wellington Management portfolio additions include Gemini Therapeutics, Design Therapeutics, Coupang, Skillz, LianBio. These companies were founded in 2020 or later.